Secreted
phospholipase A(2) group X (sPLA(2)-X) has recently been identified in the airways of patients with
asthma and may participate in
cysteinyl leukotriene (CysLT; C(4), D(4), and E(4)) synthesis. We examined CysLT synthesis and
arachidonic acid (AA) and
lysophospholipid release by eosinophils mediated by recombinant human
sPLA(2)-X. We found that recombinant
sPLA(2)-X caused marked AA release and a rapid onset of CysLT synthesis in human eosinophils that was blocked by a selective
sPLA(2)-X inhibitor. Exogenous
sPLA(2)-X released
lysophospholipid species that arise from
phospholipids enriched in AA in eosinophils, including
phosphatidylcholine,
phosphatidylinositol, and
phosphatidylethanolamine as well as plasmenyl
phosphatidylcholine and
phosphatidylethanolamine. CysLT synthesis mediated by
sPLA(2)-X but not AA release could be suppressed by inhibition of cPLA(2)α. Exogenous
sPLA(2)-X initiated Ser(505) phosphorylation of cPLA(2)α, an intracellular Ca(2+) flux, and translocation of cPLA(2)α and
5-lipoxygenase in eosinophils. Synthesis of CysLTs in response to
sPLA(2)-X or
lysophosphatidylcholine was inhibited by p38 or JNK inhibitors but not by a
MEK 1/2 inhibitor. A further increase in CysLT synthesis was induced by the addition of
sPLA(2)-X to eosinophils under conditions of
N-formyl-methionyl-leucyl-phenylalanine-mediated cPLA(2)α activation. These results indicate that
sPLA(2)-X participates in AA and
lysophospholipid release, resulting in CysLT synthesis in eosinophils through a mechanism involving p38 and JNK MAPK, cPLA(2)α, and
5-lipoxygenase activation and resulting in the amplification of CysLT synthesis during cPLA(2)α activation. Transactivation of eosinophils by
sPLA(2)-X may be an important mechanism leading to CysLT formation in the airways of patients with
asthma.